Obstetrics and Gynecology

1046 questions

Question 381Question →

Match each postpartum clinical presentation with its most accurate underlying pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

Persistent, spiking fevers on postpartum day 6 despite 72 hours of targeted broad-spectrum intravenous antibiotics; physical examination reveals a non-tender uterus.
Sudden-onset, profuse vaginal bleeding and a boggy, enlarged uterus presenting on postpartum day 14 following a seemingly uncomplicated term vaginal delivery.
Failure to establish lactation, profound fatigue, hypotension, and hyponatremia presenting 6 weeks after an emergency delivery complicated by hemorrhagic shock.
Fever, severe lower abdominal pain, marked uterine fundal tenderness, and foul-smelling lochia 48 hours after a cesarean delivery for active labor arrest.

Matches

Show answer & explanation

Answer

The correct matches are: 1) Persistent fever without uterine tenderness matches suppurative thrombosis of the deep pelvic venous drainage. 2) Delayed postpartum hemorrhage matches delayed sloughing of the placental eschar or retained products. 3) Failure to lactate and hypotension matches ischemic necrosis of the anterior pituitary gland. 4) Early postpartum fever with extreme uterine tenderness matches polymicrobial invasion of the uterine decidua.
Each clinical vignette highlights the hallmark features necessary to identify distinct postpartum complications. Endometritis is the most common cause of early postpartum fever and involves direct decidual infection. Septic pelvic thrombophlebitis is a critical diagnosis of exclusion when a puerperal fever persists despite targeted broad-spectrum antibiotics. Secondary postpartum hemorrhage is definitively characterized by late-onset bleeding due to retained fragments or abnormal involution. Finally, Sheehan syndrome is a classical ischemic pituitary injury presenting with multi-axis endocrine failure months after an index hemorrhage.

Step-by-Step Solution

1
Analyze the first clinical vignette describing a patient with antibiotic-refractory fever and a non-tender uterus.
Identify the condition as septic pelvic thrombophlebitis.
Endometritis should respond to clindamycin and gentamicin within 48-72 hours. A refractory fever with a reassuring abdominal/pelvic exam suggests deep vein suppurative thrombosis.
2
Evaluate the second vignette describing heavy vaginal bleeding occurring two weeks postpartum.
Identify the condition as secondary postpartum hemorrhage.
Bleeding occurring past the first 24 hours is classified as secondary hemorrhage, highly characteristic of retained placental fragments or failure of normal placental site involution.
3
Assess the third vignette detailing a lack of lactation and endocrine failure following hemorrhagic shock.
Identify the condition as Sheehan syndrome.
The pituitary gland is highly vascular and enlarges during pregnancy, making it exquisitely sensitive to ischemic infarction during episodes of profound hypovolemia.
4
Examine the fourth vignette presenting the classic triad of early postpartum fever, uterine tenderness, and foul lochia.
Identify the condition as postpartum endometritis.
A cesarean delivery introduces vaginal and enteric flora into the sterile uterine cavity, leading directly to a polymicrobial decidual infection.

Key Concept

The diagnosis and pathophysiologic mechanisms of primary puerperal complications (endometritis, septic pelvic thrombophlebitis, secondary hemorrhage, and Sheehan syndrome).
Question 382Question →

A 27-year-old primigravida at 20 weeks gestation comes to the prenatal clinic complaining of severe vulvar itching and a burning sensation when urinating for the past four days. She also reports a noticeable increase in vaginal discharge but denies any foul odor, abdominal cramping, or vaginal bleeding. Her pregnancy has been uncomplicated to date. Vital signs are within normal limits. Pelvic examination reveals prominent erythema and excoriation of the vulva. The vaginal walls are erythematous, and there is a thick, white, clumpy discharge adherent to the vaginal mucosa. The cervical os is visually closed and appears normal. Vaginal pH is 4.2. Microscopic examination of the discharge mixed with a potassium hydroxide (KOH) preparation reveals branching, thread-like structures with budding organisms. Which of the following is the most appropriate next step in management for this patient?

Show answer & explanation

Answer: Intravaginal clotrimazole therapy

Answer

Intravaginal clotrimazole therapy
This patient's presentation of severe vulvar pruritus, thick white clumpy discharge, normal vaginal pH (typically < 4.5), and microscopic evidence of branching pseudohyphae on a potassium hydroxide (KOH) preparation is highly diagnostic for vulvovaginal candidiasis (VVC). VVC is particularly common during pregnancy due to elevated estrogen levels causing increased vaginal glycogen stores, which promote fungal overgrowth. In pregnant patients, the treatment of choice for symptomatic VVC is a topical azole antifungal, such as intravaginal clotrimazole or miconazole, typically given for a 7-day course. Topical therapy is preferred because it effectively treats the local infection while bypassing the potential teratogenic risks associated with systemic azole absorption.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and microscopic findings.
The patient has intense vulvar pruritus, a thick clumpy vaginal discharge, a normal vaginal pH (4.2), and pseudohyphae on KOH prep.
This combination of findings is the classic diagnostic triad for acute vulvovaginal candidiasis (VVC).
2
Determine the optimal pharmacological intervention considering the patient's pregnancy status.
The patient is pregnant (20 weeks gestation). Systemic oral azole antifungals should be avoided due to documented teratogenic potential.
Treatment guidelines for VVC in pregnancy strictly recommend a 7-day course of topical vaginal azoles (such as clotrimazole or miconazole) to ensure effective microbial eradication while prioritizing fetal safety.

Key Concept

In pregnant patients, symptomatic vulvovaginal candidiasis should be treated with topical azole antifungals (e.g., intravaginal clotrimazole) rather than oral systemic therapies to avoid potential fetal harm.
Question 383Question →

A 33-year-old nulligravid woman comes to the clinic for a routine wellness examination. She states that her menstrual cycles have always been irregular, occurring every 4545 to 6060 days, with menses lasting 77 to 88 days and accompanied by heavy flow. Her medical history includes type 2 diabetes mellitus, chronic hypertension, and obesity. Her body mass index is 3838 kg/m 2^2. Pelvic examination shows a normal-appearing cervix with no visible lesions. A Pap test is performed, and the cytology report reveals atypical glandular cells. High-risk human papillomavirus testing is negative. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Colposcopy, endocervical curettage, and endometrial biopsy

Answer

Colposcopy, endocervical curettage, and endometrial biopsy
The correct answer is colposcopy, endocervical curettage, and endometrial biopsy. Atypical glandular cells (AGC) on a Pap test indicate a risk of cervical, endocervical, or endometrial adenocarcinoma. The standard initial evaluation for AGC in all patients involves colposcopy and endocervical sampling (curettage) to assess the cervix and endocervical canal. Furthermore, because AGC can also originate from the endometrium, endometrial sampling is indicated in women age 3535 years and older, as well as in women younger than 3535 years who have risk factors for endometrial neoplasia. This patient is 3333 years old but has a history of chronic anovulation (irregular, infrequent menses) and obesity, which expose her endometrium to unopposed estrogen, significantly increasing her risk for endometrial hyperplasia and cancer. Therefore, an endometrial biopsy must be included in her initial diagnostic workup.

Step-by-Step Solution

1
Identify the primary finding on the cervical cancer screening test.
The Pap test shows atypical glandular cells (AGC).
AGC is a significant finding that carries a higher risk of underlying severe pathology (cervical, endocervical, or endometrial adenocarcinoma) compared to squamous cell abnormalities.
2
Determine the baseline diagnostic requirement for all patients with AGC.
All women with AGC must undergo colposcopy and endocervical curettage (ECC).
This evaluates the exocervix and endocervical canal for pre-malignant or malignant glandular lesions.
3
Evaluate if the patient meets criteria for concurrent endometrial sampling.
The patient requires an endometrial biopsy (EMB).
Guidelines mandate adding EMB for women with AGC if they are age ≥35\geq 35 years, OR if they are <35< 35 years but have risk factors for endometrial cancer. This 33-year-old patient has significant risk factors, including obesity and chronic anovulation (irregular menses).

Key Concept

Workup of atypical glandular cells (AGC) on Pap testing
Question 384Question →

An obese 61-year-old female patient with type 2 diabetes mellitus is evaluated in the gynecology clinic for an episode of unprovoked vaginal bleeding that occurred 10 years after her final menstrual period. Arrange the following interventions in the standard chronological order for her diagnostic workup and therapeutic management, assuming abnormal findings are confirmed at each progressive step.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: Transvaginal ultrasonography, followed by Office endometrial biopsy, then Total hysterectomy with bilateral salpingo-oophorectomy, and finally Pathologic risk stratification for adjuvant radiotherapy.
In the workup of postmenopausal bleeding, the standard chronological pathway begins with transvaginal ultrasonography to assess endometrial thickness. If the stripe is greater than 4 mm, an office endometrial biopsy is performed to obtain a tissue diagnosis. If the biopsy confirms endometrial adenocarcinoma, the patient undergoes surgical staging, which typically consists of a total hysterectomy with bilateral salpingo-oophorectomy. Finally, the surgical pathology report is analyzed to stratify the patient's risk profile and determine whether adjuvant treatments, such as vaginal brachytherapy, are indicated.

Step-by-Step Solution

1
Perform transvaginal ultrasonography
Measurement of the endometrial stripe
To triage postmenopausal bleeding; a thickness of 4 mm or less generally excludes significant pathology.
2
Obtain an office endometrial biopsy
Histologic tissue diagnosis
Required to definitively diagnose endometrial hyperplasia or adenocarcinoma if the stripe is abnormally thickened.
3
Perform a total hysterectomy with bilateral salpingo-oophorectomy
Surgical removal of the uterus, tubes, and ovaries
The standard primary treatment and surgical staging procedure for early-stage endometrial cancer.
4
Conduct pathologic risk stratification
Decision on adjuvant therapy
To evaluate prognostic factors (e.g., depth of myometrial invasion, tumor grade) that dictate the need for postoperative radiotherapy.

Key Concept

The standard sequential management of postmenopausal bleeding involves initial non-invasive evaluation of the endometrium, histologic tissue diagnosis, primary surgical staging, and subsequent risk-based adjuvant therapy.
Question 385Question →

Match each patient's clinical presentation with the most appropriate contraceptive method based on efficacy, symptom management, and medical eligibility criteria.

Click a left item, then click its matching right item

Items

32-year-old woman with heavy menstrual bleeding and anemia, desiring highly effective, long-acting contraception.
29-year-old woman with a history of breast cancer currently in remission, desiring long-acting contraception.
22-year-old woman requesting an oral emergency contraceptive 96 hours (4 days) after unprotected intercourse.
27-year-old woman with a history of migraines with aura who desires a daily oral contraceptive.

Matches

Show answer & explanation

Answer

Heavy bleeding matches with Levonorgestrel IUD. Breast cancer history matches with Copper IUD. Emergency contraception at 96 hours matches with Ulipristal acetate. Migraine with aura matches with the Progestin-only pill.
Each correct pairing directly applies the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) Medical Eligibility Criteria (MEC) for contraceptive use, ensuring patients receive methods that address their specific therapeutic needs (like heavy bleeding) while avoiding methods that pose severe health risks (like hormones in breast cancer or estrogen in migraine with aura).

Step-by-Step Solution

1
Evaluate the patient with heavy menstrual bleeding.
Select the levonorgestrel-releasing intrauterine device.
This device releases local progestin that thins the endometrial lining, significantly reducing menstrual blood loss and correcting anemia.
2
Evaluate the patient with a history of breast cancer.
Select the copper intrauterine device.
Breast cancer is a hormonally sensitive malignancy. All exogenous hormones (estrogen and progestin) are strictly contraindicated. A non-hormonal copper device is required.
3
Evaluate the patient needing emergency contraception at 96 hours.
Select ulipristal acetate.
Standard oral levonorgestrel emergency contraception loses efficacy after 72 hours. Ulipristal acetate maintains efficacy for up to 120 hours.
4
Evaluate the patient with migraines with aura seeking a daily oral pill.
Select the progestin-only pill.
Combined oral contraceptives are contraindicated due to the elevated risk of ischemic stroke associated with estrogen in patients who experience migraine auras. A progestin-only pill is safe.

Key Concept

Applying WHO Medical Eligibility Criteria (MEC) to select safe and appropriate contraceptive methods based on patient comorbidities.
Question 386Question →

Match each genetic syndrome or environmental exposure with the gynecologic malignancy for which it carries the highest risk.

Click a left item, then click its matching right item

Items

Lynch syndrome
BRCA1 mutation
In utero diethylstilbestrol (DES) exposure
Persistent high-risk HPV (types 16 and 18) infection

Matches

Show answer & explanation

Answer

Lynch syndrome matches with Endometrial and ovarian carcinomas; BRCA1 mutation matches with High-grade serous ovarian and fallopian tube carcinomas; In utero DES exposure matches with Clear cell adenocarcinoma of the vagina and cervix; Persistent high-risk HPV matches with Squamous cell carcinoma of the cervix, vagina, and vulva.
Each exposure or genetic syndrome strongly predisposes patients to specific gynecologic malignancies. Lynch syndrome is associated with endometrial and ovarian cancers due to mismatch repair defects. BRCA1 mutations increase the risk for breast, ovarian, and fallopian tube cancers due to homologous recombination defects. DES exposure in utero disrupts Mullerian development, leading to clear cell adenocarcinoma of the vagina. Finally, high-risk HPV types 16 and 18 drive squamous epithelial transformation in the cervix, vagina, and vulva.

Step-by-Step Solution

1
Identify the primary gynecologic cancers associated with mismatch repair gene mutations (Lynch syndrome).
Patients with Lynch syndrome are at a significantly increased risk for endometrial cancer and ovarian cancer.
Lynch syndrome is the most common inherited syndrome predisposing to endometrial cancer.
2
Recall the gynecologic malignancies linked to homologous recombination deficiency (BRCA1).
BRCA1 is strongly associated with hereditary breast and ovarian cancer syndrome, specifically high-grade serous carcinomas of the ovary and fallopian tubes.
BRCA1 mutations impair DNA double-strand break repair, leading to these specific malignancies.
3
Associate historical pharmacological exposures with specific structural and malignant outcomes.
DES exposure in utero is a highly specific, classic risk factor for vaginal and cervical clear cell adenocarcinoma.
DES was previously used to prevent miscarriage and affected the developing Mullerian tract in female fetuses.
4
Link viral oncogenesis to lower genital tract malignancies.
HPV 16 and 18 produce E6 and E7 oncoproteins that lead to cervical, vaginal, and vulvar squamous cell carcinomas.
HPV is the necessary cause for over 90% of cervical cancers and a large portion of vaginal and vulvar cancers.

Key Concept

Risk Factors and Genetic Syndromes in Gynecologic Oncology
Question 387Question →

A 68-year-old woman comes to the office due to a 2-week history of vaginal spotting. She reached menopause 18 years ago and had not experienced any bleeding until now. Over the past month, she has also noticed new-onset breast fullness and tenderness. Her medical history is significant for type 2 diabetes mellitus and hypertension. Pelvic examination reveals a small amount of dark blood in the vaginal vault and a palpable, non-tender, 8-cm right adnexal mass. Transvaginal ultrasound demonstrates a solid and cystic right ovarian mass, and the endometrial echo complex measures 14 mm in thickness. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Endometrial tissue sampling

Answer

Endometrial tissue sampling
The patient's presentation of postmenopausal bleeding, a markedly thickened endometrium (greater than 4 mm), breast tenderness, and a solid/cystic adnexal mass is highly suspicious for an estrogen-secreting granulosa cell tumor. Chronic unopposed estrogen secretion by these tumors can lead to concurrent endometrial hyperplasia or carcinoma in up to 50% of cases. Therefore, any patient with a suspected estrogen-producing tumor and a thickened endometrium must undergo endometrial tissue sampling prior to definitive surgical management. Identifying concurrent endometrial malignancy is critical because it dictates the need for comprehensive surgical staging during the planned abdominal surgery.

Step-by-Step Solution

1
Analyze the clinical presentation
The patient has postmenopausal bleeding, an adnexal mass, and new-onset breast tenderness.
These findings strongly suggest an estrogen-secreting ovarian neoplasm, such as a granulosa cell tumor.
2
Interpret the ultrasound findings
A 14-mm endometrial stripe is markedly abnormal in a postmenopausal woman (normal is typically 4 mm or less).
Chronic unopposed estrogen from the tumor frequently leads to concurrent endometrial hyperplasia or adenocarcinoma.
3
Determine the optimal preoperative sequence
Tissue diagnosis of the endometrium must be obtained before resecting the adnexal mass.
Knowing whether the patient has concurrent endometrial cancer is essential, as it determines if comprehensive surgical staging (e.g., lymph node dissection) is required during the planned laparotomy.

Key Concept

Patients presenting with suspected estrogen-secreting ovarian tumors (e.g., granulosa cell tumors) and a thickened endometrium must undergo endometrial sampling to rule out concurrent endometrial malignancy prior to surgical intervention.
Question 388Question →

Evaluate the following patient profiles and match each with the most medically appropriate contraceptive method, adhering to the US Medical Eligibility Criteria (MEC) and specific patient preferences.

Click a left item, then click its matching right item

Items

A 25-year-old female with a history of migraines with visual aura, seeking a highly effective, maintenance-free contraceptive that lasts for several years.
A 39-year-old female who smokes one pack of cigarettes daily and explicitly requests a daily oral contraceptive medication.
A 28-year-old female with a confirmed diagnosis of Wilson disease who desires long-acting reversible contraception (LARC).
A 24-year-old female (BMI 34 kg/m²) presenting for emergency contraception 110 hours following unprotected sexual intercourse.

Matches

Show answer & explanation

Answer

Match the migraine with aura to the subdermal implant; the 39-year-old smoker to the progestin-only pill; the Wilson disease patient to the levonorgestrel IUD; and the delayed emergency contraception/high BMI patient to ulipristal acetate.
The correct matches align patient comorbidities and preferences perfectly with the CDC US Medical Eligibility Criteria (MEC). Migraine with aura and smoking in patients aged 35 or older are absolute contraindications to estrogen-containing products. Wilson disease uniquely contraindicates the copper IUD, and ulipristal acetate is the superior oral emergency contraceptive for patients presenting up to 120 hours post-coitus, particularly in the setting of obesity.

Step-by-Step Solution

1
Analyze each patient's age, medical comorbidities, and specific contraceptive preferences.
Identified contraindications: migraine with aura (no estrogen), smoking over age 35 (no estrogen), Wilson disease (no copper), and high BMI with delayed presentation for emergency contraception (reduced levonorgestrel efficacy).
Recognizing absolute contraindications (MEC 4) is the first step in safely prescribing contraceptives.
2
Map the remaining safe options to the patient's stated lifestyle preferences.
Patient 1 wants maintenance-free (implant); Patient 2 wants a daily pill (POP); Patient 3 wants LARC without copper (LNG-IUD); Patient 4 needs effective EC up to 120 hours (Ulipristal).
Patient preference directly drives adherence and continuation of the chosen contraceptive method.
3
Finalize the 1:1 matches between the clinical profiles and the provided contraceptive options.
All profiles successfully paired with a medically appropriate and preferred method.
Ensures all constraints of the matching structure are satisfied accurately.

Key Concept

Application of the US Medical Eligibility Criteria (MEC) for contraceptive use alongside patient-specific preferences and comorbidities.
Question 389Question →

A 3131-year-old woman is evaluated at the clinic for her annual wellness examination. She reports feeling well and has no pelvic pain, abnormal vaginal discharge, dyspareunia, or irregular bleeding. Her medical history is unremarkable. She is in a monogamous relationship and uses a copper intrauterine device that was inserted three years ago. Vital signs include a blood pressure of 112/70112/70 mm Hg, heart rate of 7474/min, and temperature of 36.9∘36.9^\circ C (98.4∘98.4^\circ F). Speculum examination shows a grossly normal cervix with the device strings visible at the external os. Bimanual examination reveals a mobile, anteverted uterus with no cervical motion tenderness or adnexal masses. A Papanicolaou test is obtained. One week later, the cytology report indicates negative for intraepithelial lesion or malignancy, but notes the presence of Actinomyces-like organisms. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Continue the current contraceptive method and provide reassurance

Answer

The most appropriate next step is to continue the current contraceptive method and provide reassurance.
The correct management for an asymptomatic patient with an intrauterine device (IUD) and a Pap test showing Actinomyces-like organisms is reassurance and routine observation. Actinomyces is a Gram-positive anaerobic bacterium that can be a normal commensal in the female genital tract, especially in the presence of a foreign body like an IUD. The presence of these organisms on a Pap smear without any signs of pelvic infection (such as fever, pelvic pain, or abnormal discharge) represents asymptomatic colonization. Current guidelines explicitly advise against prescribing antibiotics or removing the IUD in such cases, as the risk of developing true pelvic actinomycosis is extremely low.

Step-by-Step Solution

1
Evaluate the patient's clinical presentation.
The patient is completely asymptomatic with a normal pelvic examination.
Differentiating between asymptomatic colonization and active infection is crucial for determining management.
2
Interpret the Papanicolaou test results.
The test shows no malignant cells but notes Actinomyces-like organisms.
Actinomyces species are normal commensals of the female genital tract, particularly in women with intrauterine devices.
3
Determine the necessity of intervention.
No treatment or device removal is indicated.
Because the patient lacks symptoms of pelvic inflammatory disease (e.g., pelvic pain, fever, weight loss), this represents benign colonization, requiring only routine observation.

Key Concept

Management of Actinomyces on Pap smear in IUD users
Question 390Question →

A 29-year-old woman is evaluated in the hospital prior to discharge. Three days ago, she was admitted with severe lower abdominal pain, a temperature of 38.6∘C38.6^\circ\text{C} (101.5∘F101.5^\circ\text{F}), a blood pressure of 110/70 mmHg110/70\text{ mmHg}, and a heart rate of 112/min112\text{/min}. Pelvic examination at that time revealed purulent cervical discharge, pronounced cervical motion tenderness, and a palpable, tender left adnexal mass. A copper intrauterine device string was visible at the cervical os. Pelvic ultrasonography confirmed a 6-cm6\text{-cm} left tubo-ovarian abscess. She was admitted and started on intravenous cefoxitin and oral doxycycline. Over the past 72 hours, she has become afebrile, her heart rate has decreased to 78/min78\text{/min}, and her pelvic pain has significantly improved. Her leukocyte count has normalized to 7,500/mm37,500/\text{mm}^3. She is currently tolerating a regular diet. Endocervical nucleic acid amplification testing from admission returned positive for *Chlamydia trachomatis* and negative for *Neisseria gonorrhoeae*. Blood cultures show no growth. She will be discharged to complete a 14-day total course of therapy. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Retain the intrauterine device; prescribe oral doxycycline and oral metronidazole

Answer

The most appropriate management is to retain the intrauterine device and prescribe oral doxycycline combined with oral metronidazole.
The correct management involves retaining the intrauterine device (IUD) and prescribing oral doxycycline and oral metronidazole. For patients with pelvic inflammatory disease (PID) and a tubo-ovarian abscess (TOA) who have an IUD in place, the device does not need to be removed if the patient demonstrates clinical improvement (e.g., defervescence, decreased pain, normalizing leukocytosis) within 48 to 72 hours of starting parenteral antibiotics. Because this patient has responded well to intravenous cefoxitin and oral doxycycline, the IUD should be left in situ. Regarding step-down therapy, patients with a TOA require a full 14-day course of antimicrobials that includes robust anaerobic coverage. Because TOAs are polymicrobial and involve vaginal and gastrointestinal flora (including strict anaerobes like Bacteroides species), targeted therapy against Chlamydia trachomatis (doxycycline) is insufficient on its own. Metronidazole must be added to the oral doxycycline regimen to ensure eradication of the abscess cavity flora and prevent recurrence.

Step-by-Step Solution

1
Assess the clinical response to initial inpatient therapy.
The patient has become afebrile, hemodynamically stable, and her pain has improved over 72 hours.
Determines if conservative medical management is successful or if surgical intervention (e.g., abscess drainage, device removal) is required.
2
Determine the appropriate management of the intrauterine device (IUD).
Retain the IUD.
Guidelines recommend retaining the IUD during acute pelvic inflammatory disease unless the patient fails to improve clinically after 48-72 hours of appropriate therapy.
3
Select the optimal oral step-down antibiotic regimen.
Prescribe oral doxycycline and oral metronidazole.
Doxycycline covers the identified C. trachomatis, while metronidazole is mandatory to cover the polymicrobial anaerobic flora inherent to tubo-ovarian abscesses.

Key Concept

Management of tubo-ovarian abscess requires 14 days of broad-spectrum antimicrobial therapy including anaerobic coverage, and an intrauterine device can be retained if the patient demonstrates clinical improvement within 48-72 hours.
Estimated Time:1m 30s
Question 391Question →

A 34-year-old woman presents to the outpatient clinic complaining of severe vulvar pruritus and a thick vaginal discharge. Arrange the following clinical steps in the most appropriate chronological sequence for the evaluation and management of this patient's suspected recurrent vulvovaginal candidiasis (RVVC).

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with documenting the history of recurrences, confirming the acute infection with microscopy, obtaining a fungal culture, and finally initiating a prolonged suppressive antifungal regimen.
The evaluation of recurrent vulvovaginal candidiasis (RVVC) follows a logical progression from history to definitive treatment. First, the provider must establish the diagnosis of RVVC by confirming the patient has had at least four symptomatic episodes in the past year. Next, the current episode must be objectively confirmed via a KOH wet mount showing pseudohyphae, ruling out other etiologies. Because RVVC is frequently associated with non-albicans species, a fungal culture must be obtained. Finally, once the diagnostic workup is complete, the patient is started on an induction and six-month maintenance antifungal regimen to prevent future recurrences.

Step-by-Step Solution

1
Classify the disease pattern based on the patient's clinical history.
Document four or more episodes in a year.
Recurrent vulvovaginal candidiasis has a specific definition that changes the management pathway compared to a single, uncomplicated infection.
2
Diagnose the current acute symptomatic episode.
Visualize yeast on a KOH wet mount.
Objective microscopic confirmation of a current fungal infection is required before prescribing prolonged antifungal courses.
3
Perform specialized testing indicated for recurrent cases.
Send a vaginal fungal culture.
Standard wet mounts do not differentiate between Candida species; a culture is necessary to identify treatment-resistant non-albicans strains.
4
Initiate the appropriate therapeutic regimen for recurrent disease.
Start a six-month suppressive fluconazole regimen.
Standard short-course therapy is insufficient for recurrent disease, necessitating a prolonged maintenance strategy.

Key Concept

The management of recurrent vulvovaginal candidiasis (RVVC) requires confirming the diagnosis clinically and microscopically, obtaining a fungal culture to identify non-albicans species, and treating with a 6-month suppressive antifungal regimen.
Question 392Question →

A 29-year-old nulligravid woman with a BMI of 34 kg/m² comes to the clinic seeking evaluation for an inability to conceive over the past 14 months. She has a history of irregular menstrual cycles occurring every 45 to 60 days. Physical examination reveals moderate facial acne and terminal hair growth on her chin. Semen analysis of her partner is within normal limits, and a hysterosalpingogram demonstrates patent fallopian tubes bilaterally. Arrange the following management steps in the correct chronological sequence for this patient's anovulatory infertility, progressing from the most appropriate initial therapy to the most advanced intervention.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of treatment for anovulatory infertility in an obese patient with PCOS begins with weight loss, followed by letrozole, then exogenous gonadotropins, and finally in vitro fertilization.
The patient's presentation of infrequent menses, clinical hyperandrogenism (hirsutism, acne), and infertility in the setting of obesity is diagnostic of polycystic ovary syndrome (PCOS). Since her partner's semen analysis and her fallopian tubes are normal, the primary issue is anovulation. The treatment of PCOS-related infertility follows a strict stepwise escalation. The initial step for overweight or obese patients is lifestyle modification and weight loss, which decreases peripheral estrone conversion and insulin resistance, often restoring spontaneous ovulation. If this is unsuccessful, the first-line pharmacologic agent is letrozole, an aromatase inhibitor. If ovulation or pregnancy is not achieved after multiple cycles of letrozole, exogenous gonadotropins (FSH/LH) are utilized to directly stimulate the ovaries. In vitro fertilization (IVF) is the final, most invasive step if all other conservative and pharmacological methods fail.

Step-by-Step Solution

1
Identify the underlying cause of the patient's infertility.
The patient has oligomenorrhea and clinical hyperandrogenism in the setting of obesity, which is consistent with polycystic ovary syndrome (PCOS).
Establishing the etiology of infertility directs the specific stepwise treatment algorithm.
2
Determine the initial, least invasive therapeutic intervention.
Implementation of a diet and exercise program for weight reduction.
In obese patients with PCOS, weight loss is considered first-line management because it decreases insulin resistance and can independently restore ovulatory cycles.
3
Select the first-line pharmacologic therapy if lifestyle modifications fail.
Oral administration of letrozole.
Current guidelines recommend letrozole (an aromatase inhibitor) as the preferred first-line ovulation induction agent for PCOS due to higher live birth rates compared to clomiphene.
4
Identify subsequent steps for treatment resistance.
Exogenous gonadotropins, followed by in vitro fertilization (IVF).
Therapy logically escalates from oral agents to injectable medications (gonadotropins), and ultimately to assisted reproductive technologies (IVF) as a last resort.

Key Concept

Stepwise management of infertility in polycystic ovary syndrome (PCOS)
Estimated Time:1m 0s
Question 393Question →

A 2424-year-old woman, gravida 11, para 00, is admitted to the labor and delivery unit at 3939 weeks and 44 days of gestation in spontaneous active labor. Her prenatal course was uncomplicated. Maternal vital signs are: blood pressure 118/76 mm Hg118/76\text{ mm Hg}, pulse 82/min82/\text{min}, and temperature 37.1 C37.1\text{ C}. The estimated fetal weight is 3200 g3200\text{ g} (7 lb 1 oz7\text{ lb } 1\text{ oz}).

Cervical examination reveals the cervix is 6 cm6\text{ cm} dilated, 90%90\% effaced, and at 00 station. The fetal membranes are ruptured, and clear amniotic fluid is noted.

Over the next hour, tocodynamometry demonstrates regular uterine contractions occurring every 33 to 44 minutes. External fetal monitoring shows a baseline heart rate of 140/min140/\text{min} with moderate variability. However, there are recurrent, abrupt decreases in the fetal heart rate to 90/min90/\text{min} that last for 4040 to 6060 seconds before rapidly returning to baseline. The onset of these decreases varies in relationship to the peak of the uterine contractions.

The patient is repositioned to the left lateral decubitus position, administered a 500 mL500\text{ mL} intravenous normal saline bolus, and provided supplemental oxygen. After 3030 minutes, the fetal heart rate tracing remains unchanged with moderate variability.

Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Amnioinfusion

Answer

The correct answer is amnioinfusion.
The correct answer is amnioinfusion. The fetal heart rate (FHR) tracing describes recurrent variable decelerations, characterized by an abrupt onset to nadir in less than 3030 seconds. These decelerations are caused by umbilical cord compression, which frequently occurs after the rupture of membranes due to the loss of amniotic fluid cushioning. Initial intrauterine resuscitation for recurrent variable decelerations includes maternal repositioning, intravenous fluid administration, and supplemental oxygen. If these conservative measures fail to resolve the decelerations, amnioinfusion (instilling normal saline or lactated Ringer's into the uterine cavity via an intrauterine pressure catheter) is the next best step. It artificially restores the amniotic fluid volume, alleviating cord compression. Because the FHR tracing still demonstrates moderate variability (indicating a Category II tracing without current fetal acidemia), proceeding with amnioinfusion is safe and appropriate to prevent unnecessary surgical delivery.

Step-by-Step Solution

1
Identify the type of fetal heart rate deceleration from the clinical description.
The abrupt decreases in heart rate that vary in timing relative to contractions indicate variable decelerations.
Identifying the deceleration type determines the underlying pathophysiology (cord compression) and guides management.
2
Evaluate the response to initial intrauterine resuscitative measures.
Maternal repositioning, fluid bolus, and oxygen failed to resolve the recurrent variable decelerations.
If conservative measures fail, secondary interventions are required to alleviate cord compression and prevent fetal acidemia.
3
Assess the overall category of the fetal heart rate tracing to determine urgency.
The presence of moderate variability makes this a Category II tracing, indicating the fetus is not currently acidemic.
A Category II tracing allows time for targeted medical interventions (amnioinfusion) rather than necessitating immediate surgical delivery.

Key Concept

Amnioinfusion is the appropriate next step for recurrent variable decelerations that do not respond to initial conservative measures (repositioning, oxygen, fluids), provided the fetal heart rate tracing does not show signs of severe acidemia.
Estimated Time:1m 0s
Question 394Question →

A nulliparous woman presents to the labor unit at 40 weeks and 2 days of gestation reporting regular uterine contractions. She is 24 years old and has had an uncomplicated pregnancy. On initial assessment, her cervix is dilated to 5 cm and completely effaced, with the fetal vertex at 0 station. Over the next hour, her contractions occur every 3 minutes. The continuous fetal monitor displays a baseline heart rate of 130/min with moderate variability. However, there are recurrent, abrupt decreases in the fetal heart rate to 80/min that reach their nadir within 15 seconds. These episodes last approximately 45 seconds and occur concurrently with the majority of the contractions before rapidly returning to baseline. The nursing staff assists the patient in changing to the left lateral decubitus position and administers an intravenous normal saline bolus, but the fetal heart rate pattern does not change. A subsequent cervical examination reveals no palpable umbilical cord.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Perform an amnioinfusion

Answer

Perform an amnioinfusion
The correct answer is performing an amnioinfusion. This patient is experiencing recurrent variable decelerations, defined by abrupt decreases in the fetal heart rate (onset to nadir less than 30 seconds). Variable decelerations are caused by transient umbilical cord compression. When they become recurrent (occurring with at least half of the contractions) and do not respond to initial resuscitative measures such as maternal repositioning and intravenous fluid boluses, an amnioinfusion is the most appropriate next step. Amnioinfusion involves instilling normal saline into the uterine cavity to artificially restore amniotic fluid volume, which cushions the umbilical cord, often resolving the decelerations and preventing fetal acidemia.

Step-by-Step Solution

1
Analyze the fetal heart rate (FHR) tracing characteristics.
The tracing shows an abrupt decrease (onset to nadir < 30 seconds) in FHR, with a nadir of 80/min lasting 45 seconds, associated with contractions.
Identifying the specific type of deceleration (variable, early, or late) is required to determine the underlying pathophysiology.
2
Correlate the FHR pattern with its underlying etiology.
Abrupt FHR decreases represent variable decelerations, which are caused by umbilical cord compression.
Variable decelerations are typically reflex responses to transient cord compression during contractions.
3
Evaluate the response to initial intrauterine resuscitation.
Maternal repositioning and intravenous fluid administration failed to resolve the recurrent variable decelerations, and there is no overt cord prolapse on exam.
Initial management aims to alleviate cord compression mechanically and improve uteroplacental perfusion, but persistent decelerations require escalated intervention.
4
Select the most appropriate definitive next step.
Amnioinfusion is the appropriate step to artificially increase amniotic fluid volume and cushion the umbilical cord.
When initial measures fail, amnioinfusion can effectively relieve cord compression in the first stage of labor, often preventing the need for surgical delivery.

Key Concept

Amnioinfusion is indicated for recurrent variable decelerations that do not resolve with initial resuscitative measures (e.g., maternal repositioning, fluid bolus) to relieve umbilical cord compression and prevent fetal acidemia.
Question 395Question →

A 30-year-old woman presents to the clinic for evaluation of secondary amenorrhea. Her last menstrual period was 10 months ago, shortly after she stopped breastfeeding her first child. Her pregnancy was complicated by a severe postpartum hemorrhage requiring an emergent suction curettage. She denies headaches, visual disturbances, hot flashes, or galactorrhea. Her body mass index is 23 kg/m². Physical examination reveals normal breast development and a normal-appearing vagina and cervix. Arrange the following steps in the most appropriate sequential diagnostic algorithm to evaluate this patient's amenorrhea, from the initial test to the final definitive diagnostic procedure.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct diagnostic sequence is: 1) Serum beta-hCG, 2) Serum FSH, TSH, and prolactin, 3) Progestin challenge test, 4) Sequential estrogen-progestin challenge test, 5) Diagnostic hysteroscopy.
The evaluation of secondary amenorrhea follows a logical stepwise approach to compartmentalize the defect. First, pregnancy must be ruled out with a serum beta-hCG test. Second, systemic and hypothalamic-pituitary-ovarian axis disorders are evaluated with serum TSH, prolactin, and FSH levels. Third, a progestin challenge test is performed; lack of bleeding indicates either an estrogen-deficient state or an outflow tract obstruction. Fourth, an estrogen-progestin challenge test differentiates between these two: failure to bleed despite adequate exogenous hormones confirms an anatomic uterine defect, such as Asherman syndrome, which is strongly suspected in this patient given her history of postpartum curettage. Finally, diagnostic hysteroscopy is the gold standard to visualize and treat the resulting intrauterine synechiae.

Step-by-Step Solution

1
Exclude pregnancy
Obtain a serum beta-hCG measurement.
Pregnancy is the most common etiology of secondary amenorrhea and must be universally ruled out first.
2
Assess systemic endocrine and HPO axis function
Measure serum FSH, TSH, and prolactin.
Identifies common reversible causes like hypothyroidism, prolactinoma, or primary ovarian insufficiency.
3
Assess endogenous estrogen levels
Perform a progestin challenge test.
Evaluates if the ovaries are producing sufficient estrogen to proliferate the endometrium. Lack of withdrawal bleeding indicates either severe hypoestrogenism or an outflow tract defect.
4
Differentiate hypoestrogenism from outflow tract obstruction
Administer a sequential estrogen-progestin challenge.
Provides adequate exogenous hormone stimulation. A failure to bleed despite this confirms an unresponsive endometrium or outflow tract obstruction.
5
Directly visualize and diagnose the anatomic defect
Perform diagnostic hysteroscopy.
Provides definitive visualization and concurrent treatment of intrauterine synechiae (Asherman syndrome), which is strongly suspected given the prior curettage.

Key Concept

The step-wise diagnostic evaluation of secondary amenorrhea utilizes hormonal challenges to localize the etiology to the outflow tract, ovaries, pituitary, or hypothalamus.
Question 396Question →

A healthy 24-year-old gravida 1 para 0 at 39 weeks gestation is admitted to the maternity ward in spontaneous active labor. Her prenatal course was uncomplicated. She is currently utilizing continuous epidural analgesia and reports excellent pain control. Her temperature is 37.1°C (98.8°F), blood pressure is 120/76 mmHg, and pulse is 82/min. Uterine contractions are occurring every 3 to 4 minutes and feel firm on palpation. A sterile vaginal examination reveals the cervix is 8 cm dilated and 100% effaced, with the fetal vertex at +1 station. Continuous electronic fetal monitoring demonstrates a baseline heart rate of 145/min with moderate variability. During each uterine contraction, the fetal heart rate trace exhibits a gradual, symmetrical decrease to a nadir of 120/min. The nadir of the heart rate precisely aligns with the peak of the contraction, and the heart rate smoothly returns to baseline simultaneously with the resolution of the contraction. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Continue routine intrapartum care

Answer

Continue routine intrapartum care
The correct answer involves continuing expectant management because the patient is exhibiting early decelerations. Early decelerations are defined by a gradual decrease in fetal heart rate (onset to nadir taking ≥\geq 30 seconds) that is symmetrical and mirrors the uterine contraction. Crucially, the nadir of the deceleration occurs exactly at the peak of the contraction. This is a benign, physiologic reflex triggered by compression of the fetal head as it descends into the birth canal (consistent with this patient's 8 cm dilation and +1 station). Because this pattern does not indicate fetal hypoxia or acidemia, it is classified as a Category I tracing, and no medical or surgical intervention is indicated.

Step-by-Step Solution

1
Analyze the fetal heart rate (FHR) tracing described in the vignette.
The tracing shows a gradual, symmetrical decrease matching the contraction, with the nadir aligning exactly with the contraction peak.
Identifying the timing of the deceleration relative to the contraction distinguishes between early, late, and variable decelerations.
2
Correlate the FHR pattern with its underlying pathophysiology.
This pattern defines early decelerations, which are caused by fetal head compression leading to a vagal response.
Understanding the etiology confirms whether the finding is a sign of fetal distress or a normal part of labor.
3
Determine the necessary clinical intervention based on the physiological nature of the decelerations.
Since early decelerations are benign and do not indicate hypoxia, expectant management is required.
Intervening for a normal physiological process introduces unnecessary risk to both mother and fetus.

Key Concept

Early decelerations are benign, gradual decreases in fetal heart rate that precisely mirror uterine contractions, caused by fetal head compression during descent, and require only routine expectant management.
Estimated Time:1m 0s
Question 397Question →

A 68-year-old multiparous woman presents to her primary care physician reporting a recent episode of vaginal bleeding. She states that she noticed bright red blood on her undergarments yesterday, which was entirely unexpected as her last menstrual period occurred more than 15 years ago. Her medical history is significant for hypertension and type 2 diabetes mellitus, which are managed with lisinopril and metformin. Her vital signs are within normal limits. A speculum examination reveals a small amount of dark blood in the vaginal vault, but no cervical or vaginal lesions are visible. The bimanual examination is unremarkable. Which of the following is the most appropriate next step in the evaluation of this patient?

Show answer & explanation

Answer: Endometrial tissue sampling

Answer

Endometrial tissue sampling is the required next step to evaluate for endometrial cancer in a patient with postmenopausal bleeding.
The correct response involves directly evaluating the endometrium. In any postmenopausal woman presenting with vaginal bleeding, the immediate primary concern is endometrial carcinoma. Clinical guidelines require prompt investigation of the uterine lining, typically utilizing either endometrial tissue sampling (biopsy) or a transvaginal ultrasound to measure endometrial thickness. Given the options provided, obtaining a tissue sample is the definitive first step in establishing a diagnosis.

Step-by-Step Solution

1
Identify the primary clinical presentation.
The patient is a 68-year-old woman with a history of type 2 diabetes presenting with new-onset postmenopausal bleeding.
Recognizing postmenopausal bleeding is critical because it carries a significant risk of being caused by a gynecologic malignancy.
2
Determine the standard diagnostic protocol for this presentation.
The protocol dictates that postmenopausal bleeding must be evaluated to rule out endometrial hyperplasia or cancer.
Endometrial cancer is the most common gynecologic malignancy, and bleeding is its earliest and most common symptom.
3
Select the most appropriate initial intervention.
Direct evaluation of the endometrium via tissue sampling (or transvaginal ultrasonography) is the correct choice.
Histologic evaluation provides a definitive diagnosis and guides subsequent management.

Key Concept

Any vaginal bleeding in a postmenopausal woman requires prompt evaluation with endometrial tissue sampling or transvaginal ultrasound to rule out endometrial carcinoma.
Question 398Question →

A 59-year-old woman is evaluated in the gynecology clinic for a persistent, clear vaginal discharge over the past three months. She has not experienced any vaginal bleeding. Menopause occurred 8 years ago. Her past medical history is significant for type 2 diabetes mellitus and a body mass index of 37 kg/m². Current medications include metformin and lisinopril. On speculum examination, the vaginal mucosa appears pale and thin, and the cervix has no visible lesions or bleeding. Bimanual examination reveals a small, mobile uterus and no adnexal masses. A cervical cytology specimen is collected, which subsequently returns positive for atypical glandular cells. To further investigate, the physician performs a transvaginal ultrasound in the office, which demonstrates normal-sized ovaries and an endometrial stripe measuring 3 mm in thickness. Based on these findings, which of the following is the most appropriate next step in the patient's management?

Show answer & explanation

Answer: Colposcopy with endocervical curettage and endometrial biopsy

Answer

Colposcopy with endocervical curettage and endometrial biopsy
The correct management for this patient is colposcopy with endocervical curettage and endometrial biopsy. Atypical glandular cells (AGC) on cervical cytology can originate from the cervix, endometrium, or occasionally the fallopian tubes or ovaries. In women age 35 and older, or in younger women with risk factors for endometrial cancer (e.g., obesity, diabetes, chronic anovulation), clinical guidelines mandate comprehensive evaluation of both the cervix and the endometrium. This consists of colposcopy, endocervical sampling, and endometrial biopsy. A common and dangerous pitfall is attempting to use transvaginal ultrasound to triage these patients. While a transvaginal ultrasound endometrial stripe of 4 mm or less is highly reassuring in the setting of isolated postmenopausal bleeding, it is not an acceptable substitute for histologic sampling in patients with AGC. The finding of a 3 mm stripe in this patient does not eliminate the requirement for an endometrial biopsy.

Step-by-Step Solution

1
Identify the primary abnormal finding in the clinical vignette.
The patient has atypical glandular cells (AGC) on a routine Papanicolaou test.
AGC is a high-risk cytology result that is managed differently than atypical squamous cells, given its strong association with cervical, endometrial, and adnexal adenocarcinomas.
2
Evaluate patient demographics and risk factors relevant to the abnormal cytology.
The patient is 59 years old, postmenopausal, obese, and diabetic, placing her at high risk for endometrial hyperplasia and carcinoma.
Current guidelines stratify AGC management based on an age cutoff of 35 years and the presence of endometrial cancer risk factors.
3
Determine the mandatory diagnostic modalities for this demographic presenting with AGC.
Comprehensive sampling of the cervix (colposcopy and endocervical curettage) and the endometrium (endometrial biopsy) is required.
Atypical glandular cells can originate from the endocervix or the endometrium; therefore, both anatomical sites must be histologically evaluated simultaneously.
4
Assess the impact of the transvaginal ultrasound finding on the management algorithm.
The 3 mm endometrial stripe does not alter the management plan; the endometrial biopsy remains mandatory.
While a thin endometrial stripe is reassuring in isolated postmenopausal bleeding, it is not an acceptable triage tool for AGC, as endometrial cancers presenting with AGC may not uniformly thicken the endometrium.

Key Concept

In women age 35 and older, or those with risk factors for endometrial cancer, the finding of atypical glandular cells (AGC) on cervical cytology mandates colposcopy, endocervical curettage, and endometrial biopsy, regardless of transvaginal ultrasound findings.
Question 399Question →

A 33-year-old gravida 2, para 1, at 39 weeks gestation is admitted to the hospital in active labor. Her prenatal course was uncomplicated. Her previous pregnancy resulted in a low transverse cesarean delivery due to breech presentation. She strongly desires a vaginal birth and is undergoing a trial of labor after cesarean. Upon admission, cervical examination shows 5 cm dilation and 90% effacement, with the fetal head at -1 station. Epidural analgesia is administered with excellent effect. Three hours later, the patient suddenly complains of a sharp, tearing lower abdominal pain that radiates to her right shoulder, breaking through the epidural block. Concurrently, the fetal heart rate monitor demonstrates a sudden, prolonged deceleration to 75/min that has persisted for 4 minutes. A repeat cervical examination reveals 5 cm dilation and the fetal presenting part is now palpable at -3 station. Maternal blood pressure is 90/50 mm Hg and pulse is 118/min. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Emergency laparotomy

Answer

Emergency laparotomy
The correct answer is emergency laparotomy. This patient is experiencing a uterine rupture, a life-threatening complication most commonly seen in patients undergoing a trial of labor after a previous cesarean delivery. The classic presentation includes sudden breakthrough abdominal pain, a nonreassuring fetal heart rate tracing (most commonly a prolonged deceleration or bradycardia), maternal hemodynamic instability, and a pathognomonic loss of fetal station as the fetus retracts into the abdominal cavity. Furthermore, blood irritating the diaphragm (hemoperitoneum) commonly causes referred shoulder pain (Kehr's sign). The definitive management is an immediate laparotomy for delivery of the fetus and repair of the uterine defect (or hysterectomy) to control hemorrhage.

Step-by-Step Solution

1
Identify the risk factors and the acute clinical presentation.
The patient is undergoing a trial of labor after cesarean (TOLAC) and presents with acute breakthrough abdominal pain, referred shoulder pain, hypotension, and fetal bradycardia.
Patients with a history of prior cesarean delivery have a uterine scar that is susceptible to tearing under the stress of labor.
2
Analyze the pelvic examination findings.
The fetal presenting part has retracted from -1 station to -3 station.
Loss of fetal station is a pathognomonic sign that the fetus has been extruded through a uterine defect into the maternal abdominal cavity.
3
Determine the definitive management based on the diagnosis of uterine rupture.
Immediate surgical intervention is required.
Uterine rupture causes massive intra-abdominal hemorrhage (hemoperitoneum) and fetal asphyxia, necessitating an emergency laparotomy for delivery and uterine repair.

Key Concept

Recognition and management of uterine rupture during a trial of labor after cesarean (TOLAC)
Question 400Question →

A 3838-year-old G2P2 woman comes to the office seeking a reliable method of contraception. She also reports that over the past 88 months, her menstrual periods have become increasingly heavy. She states that her menses last for 77 to 88 days and she frequently soaks through a thick pad every 22 hours on the heaviest days. Her menstrual cycles remain regular, occurring every 2828 days. Her medical history is significant for frequent migraines with aura since age 2020. She smokes one pack of cigarettes daily. Her only medication is sumatriptan as needed. Vital signs include a blood pressure of 118/76 mmHg118/76 \text{ mmHg}, pulse of 72/min72\text{/min}, and BMI of 23 kg/m223 \text{ kg/m}^2. Pelvic examination reveals a normal-sized, mobile uterus without adnexal masses. A urine pregnancy test is negative. Laboratory studies show a hemoglobin of 10.8 g/dL10.8 \text{ g/dL} and a normal thyroid-stimulating hormone level. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Placement of a levonorgestrel-releasing intrauterine device

Answer

Placement of a levonorgestrel-releasing intrauterine device
This patient requires contraception and management of heavy menstrual bleeding. The levonorgestrel-releasing intrauterine device (LNG-IUD) is the most appropriate choice because it provides highly effective, long-acting contraception and is considered first-line medical therapy for heavy menstrual bleeding. The progestin in the IUD causes endometrial atrophy, significantly reducing menstrual blood loss and treating her underlying anemia. Furthermore, her history of migraines with aura and smoking at age 38 are both independent, absolute contraindications (WHO Medical Eligibility Criteria category 4) to any estrogen-containing contraceptive due to the unacceptably high risk of ischemic stroke and thromboembolism. Progestin-only methods like the LNG-IUD remain safe for this demographic.

Step-by-Step Solution

1
Identify the patient's primary clinical needs from the presentation.
The patient requires highly effective contraception and medical management for regular but heavy menstrual bleeding complicated by mild anemia.
Addressing all chief complaints ensures comprehensive and appropriate patient care.
2
Evaluate the patient's medical history against the WHO Medical Eligibility Criteria (MEC) for contraceptive use.
The patient has migraines with aura and is a smoker aged 35 or older. Both conditions are Category 4 (unacceptable health risk) for combined hormonal contraceptives (estrogen-containing methods).
Exogenous estrogen significantly increases the risk of ischemic stroke and deep vein thrombosis in patients with these specific cardiovascular and neurologic risk factors.
3
Assess the remaining contraceptive options for their ability to manage heavy menstrual bleeding.
Non-estrogen methods (progestin-only pills, implants, IUDs) are safe. Among these, the levonorgestrel-releasing IUD is the most effective at thinning the endometrium and reducing menstrual blood loss.
A copper IUD would provide safe contraception but is contraindicated for heavy menstrual bleeding as it can exacerbate the condition.
4
Determine if further diagnostic testing is required before initiating therapy.
No further testing is needed. She is under 45 with no risk factors for endometrial cancer (normal BMI, regular cycles), so biopsy is not indicated. Her TSH is normal, ruling out primary thyroid dysfunction.
Avoiding unnecessary invasive procedures or redundant laboratory testing is a key component of high-value care.

Key Concept

Medical Eligibility Criteria for Contraceptive Use and Management of Heavy Menstrual Bleeding
PreviousPage 20 / 53Next
Obstetrics and Gynecology Practice Questions — USMLE Step 2 CK — Page 20 | Examkin